SKYE · Skye Bioscience, Inc. · Executive Compensation
$1.68
+0.08 (+5.00%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“If adequate funds are not available to the Company when needed it will be required to curtail or perhaps cease operations which would, in turn, further raise substantial doubt about its ability to continue as a going concern. These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern within one year after the date that these financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$7.39M
Shares
4.43M
Volume · Oct 2
11.13K
Avg daily vol (29 sessions)
82.67K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Punit Dhillon | Chief Executive Officer | $1,361,831 |
| Kaitlyn Arsenault | Former Chief Financial Officer | $888,589 |
| Tu Diep | Chief Operating Officer | $875,939 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Punit Dhillon | Chief Executive Officer | $6,139,625 |
| Kaitlyn Arsenault | Chief Financial Officer | $2,266,825 |
| Tu Diep | Chief Operating Officer | $2,207,168 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Punit Dhillon | Chief Executive Officer | $1,807,338 |
| Kaitlyn Arsenault | Chief Financial Officer | $1,270,290 |
| Tu Diep | Chief Operating Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Punit Dhillon | CEO | $668,481 |
| Kaitlyn Arsenault | Chief Financial Officer | $469,087 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Punit Dhillon | principal financial and accounting officer | Appointed | 2026-09-11 |
| John P. Sharp | Chief Financial Officer and principal financial and accounting officer | Resigned | 2026-09-11 |
| Dr. Cliff Jones | Chief Technical Officer | Appointed | 2026-08-14 |
| Dr. Mei-Lun Wang | Chief Medical Officer | Appointed | 2026-08-14 |
| Dr. Caroline Phillips | Chief Scientific Officer | Appointed | 2026-08-14 |
| Peter Collum | Chief Financial Officer | Appointed | 2026-08-14 |
| Lisa Anson | Chief Executive Officer | Appointed | 2026-08-14 |
| Tu Diep | executive officer | Resigned | 2026-08-14 |
| Punit Dhillon | Chief Executive Officer | Resigned | 2026-08-14 |
| John P. Sharp | Chief Financial Officer | Appointed | 2026-04-03 |
| Punit Dhillon | principal accounting officer | Appointed | 2026-02-20 |
| Paul Grayson | Chairman of the Board | Appointed | 2024-10-29 |
| Puneet S. Arora, MD, MS, FACE | Chief Medical Officer | Appointed | 2024-09-04 |
| Keith Ward, PhD | member of the Board | Resigned | 2024-07-03 |
| Praveen Tyle, PhD | member of the Board | Resigned | 2024-07-03 |
| Karen L. Smith MD, PhD, MBA, LLM | director | Appointed | 2024-07-03 |
| Margaret Dalesandro | member of the Board | Resigned | 2024-03-04 |
| Annalisa Jenkins | director | Appointed | 2024-03-04 |
| Paul Grayson | Venture Partner, Versant & CEO, Tentarix | Appointed | 2023-08-21 |
| Andy Schwab | Managing Partner, 5AM Ventures | Appointed | 2023-08-21 |
| Paul Grayson | Board | Appointed | 2023-08-21 |
| Andrew Schwab | Board | Appointed | 2023-08-21 |
| Dr. Deborah Charych, Ph.D. | director | Appointed | 2023-02-16 |
| Bobby Rai | member of the Board of Directors | Resigned | 2023-02-16 |
| Bobby Rai | member of the Nominating and Corporate Governance Committee of the Board | Appointed | 2023-01-06 |